Angelos M. Stergiou, M.D., Sc.D. h.c.

Angelos M. Stergiou, M.D., Sc.D. h.c.

President and Chief Executive OfficeratSELLAS Life Sciences Group· In proxies 2022–2025

Pay in FY2022SELLAS Life Sciences Group stock -57.3% the same year

Angelos M. Stergiou, M.D., Sc.D. h.c. was paid $2.0M in FY2022 (Dec). SELLAS Life Sciences Group stock fell 57.3% that year.

Pay$100 in the stock at the end of FY21 → $43
Pay is from the Summary Compensation Table of each SELLAS Life Sciences Group proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. SELLAS Life Sciences GroupPublic company · 4 yr
    • President and Chief Executive Officer2022 – Present · 4 yrStock in role +78%
  2. Cleara Biotech B.VPublic company · 4 yr
    • Director2022 – Present · 4 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?